Over the past six months, Merck’s stock price fell to $80.05. Shareholders have lost 6.6% of their capital, which is ...

Merck (MRK) recently announced positive topline results from its Phase 3 KEYNOTE-905 trial, showcasing efficacy for KEYTRUDA in patients with muscle-invasive bladder cancer, which adds substantial ...

Merck's Phase 3 trial shows Keytruda plus Padcev improves survival in muscle-invasive bladder cancer patients ineligible for ...

Pfizer (NYSE:PFE) and Astellas Pharma (OTCPK:ALPMF) announced on Tuesday that their jointly developed antibody-drug conjugate ...

This week, Merck filed a notice in accordance with New Jersey's WARN Act, indicating it plans to eliminate 58 positions at ...

WinRevair’s Phase 3 HYPERION trial was stopped early for efficacy, with positive top-line results announced in the month ...

Merck (MRK) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts ...

IO Biotech (IOBT) stock rallies as cancer vaccine, Cylembio, with Merck's (MRK) Keytruda outperforms in a late-stage trial ...

Merck said on Tuesday it was extending its pause on Gardasil shipments to China until at least the end of 2025 due to ...

Merck said it is embarking on a multi-year cost-savings plan, which includes cuts to its workforce and real-estate footprint, ...

Written by Zacks Equity Research for Zacks -> A month has gone by since the last earnings report for Merck (MRK). Shares have added about 3.9% in that time frame, outperforming the S&P 500.

Merck & Co said on Tuesday it was extending its hold on Gardasil shipments to China until at least the end of 2025 due to persistent weakness in demand for the blockbuster human papillomavirus vaccine ...